Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma

Molecular Cancer Therapeutics

Volumn 7, Issue 3, 2008, Pages 648-658

  Ding, Yan ^a   Boguslawski, Elissa A ^a   Berghuis, Bree D ^a   Young, John J ^a   Zhang, Zhongfa ^a   Hardy, Kim ^a   Furge, Kyle ^a   Kort, Eric ^a   Frankel, Arthur E ^b   Hay, Rick V ^a   Resau, James H ^a   Duesbery, Nicholas S ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; VASCULOTROPIN;

ARTICLE; BACILLUS ANTHRACIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL COUNT; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; ECHOGRAPHY; ENZYME ACTIVITY; ENZYME INACTIVATION; FIBROSARCOMA; HUMAN; HUMAN CELL; HYPOTHESIS; IMAGING SYSTEM; IN VITRO STUDY; LEIOMYOSARCOMA; LIPOSARCOMA; MALIGNANT FIBROUS HISTIOCYTOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; TISSUE PERFUSION; TUMOR NECROSIS; TUMOR VASCULARIZATION; WESTERN BLOTTING;

ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; FIBROSARCOMA; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 41649100471     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2229     Document Type: Article

References (51)

1. English J, Pearson G, Wilsbacher J, et al. New insights into the control of MAP kinase pathways. Exp Cell Res 1999;253:255-70.
2. Bodart JF, Chopra A, Liang X, Duesbery N. Anthrax, MEK and cancer. Cell Cycle 2002;1:10-5.
3. Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000;19:6594-9.
4. Gupta S, Stuffrein S, Plattner R, et al. Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells. Mol Cell Biol 2001;21:5846-56.
5. Gupta S, Plattner R, Der CJ, Stanbridge EJ. Dissection of Ras-dependent signaling pathways controlling aggressive tumor growth of human fibrosarcoma cells: evidence for a potential novel pathway. Mol Cell Biol 2000;20:9294-306.
6. Plattner R, Gupta S, Khosravi-Far R, et al. Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. Oncogene 1999;18:1807-17.
7. Mauro A, Ciccarelli C, De Cesaris P, et al. PKCα-mediated ERK, JNK and p38 activation regulates the myogenic program in human rhabdomyosarcoma cells. J Cell Sci 2002;115:3587-99.
8. Coltella N, Manara MC, Cerisano V, et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J 2003;17:1162-4.
9. Sodhi A, Montaner S, Patel V, et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1α. Cancer Res 2000;60:4873-80.
10. Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998;391:86-9.
11. Duesbery NS, Resau J, Webb CP, et al. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci U S A 2001;98:4089-94.
12. Singh Y, Liang X, Duesbery NS. Pathogenesis of Bacillus anthracis: the role of anthrax toxins. In: Proft T, editor. Microbial toxins molecular and cellular biology. Norfolk (England): Horizon Bioscience; 2005. p. 285-312.
13. Park S, Leppla SH. Optimized production and purification of Bacillus anthracis lethal factor. Protein Expr Purif 2000;18:293-302.
14. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76-85.
15. Ridler T, Calvard S. Picture thresholding using an iterative selection method. IEEE Trans Man Cybernet 1978;6:629-32.
16. Seul M, O'Gorman L, Sammon MJ. Practical algorithms for image analysis: description, examples, and code [v, 295 p.:]. Cambridge (NY): Cambridge University Press; 2000.
17. Cobb MH. MAP kinase pathways. Prog Biophys Mol Biol 1999;71:479-500.
18. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5:810-6.
19. Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Vande Woude GF. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci U S A 2002;99:3052-7.
20. Abi-Habib RJ, Singh R, Leppla SH, et al. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice. Clin Cancer Res 2006;12:7437-43.
21. Dubel S, Little M. Microtubule-dependent cell cycle regulation is implicated in the G2 phase of Hydra cells. J Cell Sci 1988;91:347-59.
22. Pedrali-Noy G, Spadari S, Miller-Faures A, Miller AO, Kruppa J, Koch G. Synchronization of HeLa cell cultures by inhibition of DNA polymerase a with aphidicolin. Nucleic Acids Res 1980;8:377-87.
23. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
24. Streit M, Riccardi L, Velasco P, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci U S A 1999;96:14888-93.
25. Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WM. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 2006;169:1875-85.
26. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001;19:577-83.
27. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86.
28. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-8.
29. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-8.
30. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
31. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
32. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42.
33. Pages G, Berra E, Milanini J, Levy AP, Pouyssegur J. Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem 2000;275:26484-91.
34. Milanini J, Vinals F, Pouyssegur J, Pages G. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 1998;273:18165-72.
35. D'Angelo G, Struman I, Martial J, Weiner RI. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci U S A 1995;92:6374-8.
36. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997;15:2169-77.
37. Pedram A, Razandi M, Levin ER. Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 1998;273:26722-8.
38. Ennis BW, Fultz KE, Smith KA, et al. Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase. J Pharmacol Exp Ther 2005;313:325-32.
39. Shin EY, Kim SY, Kim EG. c-Jun N-terminal kinase is involved in motility of endothelial cell. Exp Mol Med 2001;33:276-83.
40. Depeille P, Young J, Boguslawski E, et al. Anthrax lethal toxin inhibits growth of and VEGF release from endothelial cells expressing the HHV8 vGPCR. Clin Cancer Res 2007;13:5926-34.
41. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296:2404-7.
42. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
43. Mavria G, Vercoulen Y, Yeo M, et al. ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell 2006;9:33-44.
44. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinicopathological features and prognosis. Int J Cancer 2002;100:463-71.
45. Feldman AL, Pak H, Yang JC, Alexander HR, Jr., Libutti SK. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer 2001;91:1525-9.
46. Ausprunk DH, Falterman K, Folkman J. The sequence of events in the regression of corneal capillaries. Lab Invest 1978;38:284-94.
47. Stupack DG, Cheresh DA. Apoptotic cues from the extracellular matrix: regulators of angiogenesis. Oncogene 2003;22:9022-9.
48. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202.
49. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA. Identification of the cellular receptor for anthrax toxin. Nature 2001;414:225-9.
50. Rogers MS, Christensen KA, Birsner AE, et al. Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth. Cancer Res 2007;67:9980-5.
51. Depeille PE, Ding Y, Bromberg-White JL, Duesbery NS. MKK signaling and vascularization. Oncogene 2007;26:1290-6.